Table 1. Upfront platinum-based chemotherapy for BMs from NSCLC.
| Author (Ref.) | Regimen | No. of patients | IRR (%) | mOS (months) |
|---|---|---|---|---|
| Cotto et al. (31) | Cisplatin/fotemustine | 31 | 23 | 5 |
| Minotti et al. (32) | Cisplatin/teniposide | 23 | 35 | 5.2 |
| Franciosi et al. (33) | Cisplatin/etoposide | 43 | 37 | 8 |
| Fujita et al. (34) | Cisplatin/ifosfamide/irinotecan | 30 | 50 | 12.7 |
| Bernardo et al. (35) | Carboplatin/vinorelbine/gemcitabine | 22 | 45 | 7 |
| Cortes et al. (36) | Cisplatin/paclitaxel/vinorelbine or cisplatin/paclitaxel/gemcitabine | 26 | 38 | 5.3 |
BMs, brain metastases; NSCLC, non-small cell lung cancer; IRR, response rate; mOS, median overall survival.